Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    stx209
Show Display Options
RSS Create an RSS feed from your search for:
stx209
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
2 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
3 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
4 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
5 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
6 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
7 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
8 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
9 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
10 Completed One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Drug: arbaclofen
11 Completed A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Condition: Alcohol Use Disorder
Interventions: Drug: Arbaclofen Placarbil;   Drug: Placebo
12 Recruiting To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
Conditions: Multiple Sclerosis;   Sperm
Interventions: Drug: arbaclofen ER Tablets;   Drug: Placebo for arbaclofen ER tablets
13 Completed Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: arbaclofen;   Drug: baclofen;   Drug: Placebo
14 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
15 Completed Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Arbaclofen placarbil 15 mg BID;   Drug: Placebo;   Drug: Arbaclofen placarbil 30 mg BID;   Drug: Arbaclofen placarbil 45 mg BID
16 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
17 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
18 Completed A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil-Cohort 1;   Drug: Placebo-Cohort 5;   Drug: arbaclofen placarbil-Cohort 2;   Drug: arbaclofen placarbil-Cohort 3;   Drug: arbaclofen placarbil-Cohort 4;   Drug: PPI
19 Completed A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Condition: Back Pain
Interventions: Drug: Arbaclofen placarbil, 20 mg;   Drug: Placebo;   Drug: Arbaclofen placarbil, 30 mg;   Drug: Arbaclofen placarbil, 40 mg
20 Completed A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
Condition: GERD
Interventions: Drug: XP19986 CR;   Drug: Placebo for XP19986 CR

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.